Aphios Receives U.S. Patent Allowance for Groundbreaking Room Temperature-Stable, Single-Shot mRNA COVID-19 Vaccine
NORTH READING, Mass.--(BUSINESS WIRE)--Aphios Corporation is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application (Application No. 17/699,359), titled 'Room Temperature-Stable, Single-Shot mRNA Vaccine for COVID-19.' This milestone validates Aphios' innovative approach to solving some of the most critical limitations of current mRNA vaccine technologies.
'By eliminating cold chain barriers and reducing the need for boosters, we're positioning this technology to serve not only in the fight against COVID-19 but also in preparation for future pandemics.'
The newly allowed patent covers a next-generation COVID-19 vaccine platform that utilizes a proprietary double nanoencapsulation system. This system first embeds mRNA molecules encoding the SARS-CoV-2 spike protein in Lipid Nanoparticles (LPN) or P hospholipid Nanosomes and then coats them with biodegradable polymer nanospheres using Aphios' green SuperFluids™ technology. This novel method enables extended release of the mRNA and, importantly, allows the vaccine to remain stable at room or refrigerator temperature, eliminating the need for ultra-cold storage and complex distribution infrastructure.
Current mRNA vaccines, while highly effective, are constrained by storage requirements of -70°C or -20°C, multiple doses, and PEG-related hypersensitivity concerns. Aphios' patented solution addresses these issues head-on by offering a PEG-free, single-dose vaccine with sustained antigen release and broad scalability for global deployment.
'This patent marks a major step forward in Aphios' mission to make vaccines more accessible, practical, and safer for people worldwide,' said Dr. Trevor P. Castor, Founder and CEO of Aphios. 'By eliminating cold chain barriers and reducing the need for boosters, we're positioning this technology to serve not only in the fight against COVID-19 but also in preparation for future pandemics.'
The invention has broader applicability for other viral infectious diseases, particularly in regions lacking advanced medical infrastructure. The continuous-flow, solvent-free encapsulation process ensures a high level of safety, environmental sustainability, and manufacturability.
With this allowance, Aphios is actively preparing for further development and regulatory advancement, while exploring strategic partnerships for clinical trials, manufacturing, and global distribution.
About Aphios Corporation:
Aphios Corporation is an emerging growth, biotechnology company developing green enabling technology platforms to improve drug discovery and manufacturing, nanotechnology drug delivery and pathogenic safety. Based on these platforms, Aphios is developing enhanced therapeutics to sustainably improve quality-of-life, and prevent and treat chronic diseases including cancers and supportive care, infectious diseases such as HIV/AIDS, influenza and COVID-19, and chronic CNS disorders such as Alzheimer's disease, pain, addiction and anxiety.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the agreement, each CVAC share will be exchanged for approximately $5.46 worth of BNTX American Depositary Shares (ADS), implying a total equity value of around $1.25 billion for CureVac. The consideration per ADS represents a premium of 55% to CVAC's three-month volume-weighted average price of approximately $3.53 as of June 11, 2025. Subject to the closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. The closing of the transaction, expected in 2025, is based on the fulfillment of certain customary closing conditions and required regulatory approvals. Year to date, shares of CureVac have surged 61% against the industry's 4.8% decline. Image Source: Zacks Investment Research The acquisition of CureVac will help BioNTech enhance its capabilities in advancing investigational mRNA-based cancer immunotherapies by expanding its research, development, manufacturing and commercialization infrastructure. It complements BioNTech's existing strengths in mRNA design, delivery technologies and production. BNTX's Comirnaty is the first approved mRNA-based vaccine for COVID-19, which was developed in collaboration with Pfizer. Strategically, the deal will allow BioNTech to expand beyond its existing oncology pipeline and focus on its newer programs across several tumor types, including key assets like its mRNA-based cancer candidates and BNT327, a PD-L1xVEGF-A bispecific antibody. We remind the investors that earlier in June, BioNTech signed a strategic collaboration agreement with Bristol Myers BMY for the global co-development and co-commercialization of BNTX's BNT327, as monotherapy and in combinations, across numerous solid tumor types. BMY will pay $1.5 billion upfront, with $2 billion in additional payments through 2028 and up to $7.6 billion in milestones. BioNTech and Bristol Myers will equally share costs and profits. BNT327 is in late-stage, potentially registrational clinical studies for two different lung cancer indications. Another phase III study evaluating the candidate in triple-negative breast cancer is planned to start by the end of 2025. Early data show promising synergy in targeting two key cancer pathways. CureVac N.V. price-consensus-chart | CureVac N.V. Quote CureVac currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Immunocore IMCR, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, loss per share estimates for Immunocore's 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained 7.5% year to date. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report CureVac N.V. (CVAC) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
35 minutes ago
- Yahoo
Billionaire Chamath Palihapitiya hints at new SPAC despite community backlash
Billionaire Chamath Palihapitiya hints at new SPAC despite community backlash originally appeared on TheStreet. Billionaire investor and former Facebook executive Chamath Palihapitiya is one of the public figures from the traditional industry whose views are paid attention to by the crypto community. Recently, the billionaire hailed the public debut of Circle (NYSE: CRLC), the company behind the USDC stablecoin. He praised Circle for building the entire market structure for stablecoins early on. Palihapitiya, currently CEO at Social Capital, has launched a dozen special-purpose acquisition companies (SPACs). A SPAC is a publicly traded shell company formed with the purpose of acquiring or merging with a private company to take it public. The investor recently asked his X followers via a poll if he should launch another SPAC. But the X community is hardly supportive. Though his post has generated 2.4 million views so far, the response has been overwhelmingly negative. Not only did 71.3% of the responses say "No," the post even got a community note claiming that SPACs launched by Chamath during Covid years have generated "horrible returns," falling as much as 70% since their peaks. Regardless of the negative response, Palihapitiya wrote in the next X post that he received calls from many "Wall Street and Crypto Titans." He added: "I will probably do it." Palihapitiya said he will include the X poll and the community note in every SEC filing possible and hoped it will "maybe" go better this time. While nobody can tell if and when Palihapitiya will launch another SPAC, the crypto community was quick to jump in to trade opinions. Traders on Polymarket, the leading crypto-based prediction market, began to bet on him launching the company by Dec. 31, 2025. For now, the odds are sitting around 57% for "Yes," which means more than half of the Polymarket traders think Palihapitiya will launch a SPAC by the end of the year. Billionaire Chamath Palihapitiya hints at new SPAC despite community backlash first appeared on TheStreet on Jun 20, 2025 This story was originally reported by TheStreet on Jun 20, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hill
3 hours ago
- The Hill
New COVID variant causes ‘razor blade throat'
Patients and doctors say the latest COVID-19 variant spreading in the U.S. in some cases causes a sore throat so painful it has earned the nickname 'razor blade throat.' The 'Nimbus' variant, which is officially known as NB.1.8.1., is a descendant of the Omicron is currently being monitored by the World Health Organization. 'Your throat is so dry, so cracked, it's so painful, it's even hard to drink sometimes,' Muhammad Azam, a physician with Sharp Community Medical Group in California, told ABC 10. The variant was first identified in January. It has since been found around the globe, including in Canada and at least 13 states in the U.S. Apart from 'razor blade throat,' it causes symptoms similar to other Omicron variants of the virus, like cough, fever, fatigue, muscle aches, congestion, headache, nausea, vomiting and loss of smell or taste, according to the Centers for Disease Control and Prevention. 'Sore throat has been a part of the spectrum of COVID from the beginning,' said Amesh Adalja, senior scholar at the Johns Hopkins Center for Health Security. 'It is something that we know occurs just like it occurs with many other respiratory viruses.' Most cases of COVID-19 in the U.S. are still caused by the LP.8.1. strain, but the NB.1.8.1 variant is becoming increasingly prominent. According to CDC data, 38 percent of COVID cases stem from the LP.8.1 strain while 37 percent of COVID cases now stem from the 'Nimbus' variant. The agency notes on its website that, given the low number of virus sequences being reported, its precision is low. NB.1.8.1 does not appear to be any more of a global threat than other variants, according to the WHO. The organization also said that the existing COVID-19 vaccines provide adequate protection against severe illness and hospitalization caused by the new variant. Dr. Peter Chin-Hong, a professor of medicine and infectious disease specialist at the University of California, San Francisco, told ABC News that most COVID patients are reporting sore throat. 'I think it's certainly amongst the spectrum of symptoms that you can get, and we know that sore throat is reported by about 70% of patients now with COVID, so it's not unusual, and like with everything in medicine, there's always a spectrum,' he said.
